Modulation of Neuronal Damage in DRG by Asprosin in a High-Glucose Environment and Its Impact on miRNA181-a Expression in Diabetic DRG

dc.contributor.authorAdam, Muhammed
dc.contributor.authorOzcan, Sibel
dc.contributor.authorDalkilic, Semih
dc.contributor.authorTektemur, Nalan Kaya
dc.contributor.authorTekin, Suat
dc.contributor.authorBilgin, Batuhan
dc.contributor.authorOzcan, Mete
dc.date.accessioned2026-08-12T17:38:35Z
dc.date.issued2024
dc.departmentFırat Üniversitesi
dc.description.abstractAsprosin, a hormone secreted from adipose tissue, has been implicated in the modulation of cell viability. Current studies suggest that neurological impairments are increased in individuals with obesity-linked diabetes, likely due to the presence of excess adipose tissue, but the precise molecular mechanism behind this association remains poorly understood. In this study, our hypothesis that asprosin has the potential to mitigate neuronal damage in a high glucose (HG) environment while also regulating the expression of microRNA (miRNA)-181a, which is involved in critical biological processes such as cellular survival, apoptosis, and autophagy. To investigate this, dorsal root ganglion (DRG) neurons were exposed to asprosin in a HG (45 mmol/L) environment for 24 hours, with a focus on the role of the protein kinase A (PKA) pathway. Expression of miRNA-181a was measured by using real-time polymerase chain reaction (RT-PCR) in diabetic DRG. Our findings revealed a decline in cell viability and an upregulation of apoptosis under HG conditions. However, pretreatment with asprosin in sensory neurons effectively improved cell viability and reduced apoptosis by activating the PKA pathway. Furthermore, we observed that asprosin modulated the expression of miRNA-181a in diabetic DRG. Our study demonstrates that asprosin has the potential to protect DRG neurons from HG-induced damage while influencing miRNA-181a expression in diabetic DRG. These findings provide valuable insights for the development of clinical interventions targeting neurotoxicity in diabetes, with asprosin emerging as a promising therapeutic target for managing neurological complications in affected individuals.
dc.description.sponsorshipTrkiye Bilimsel ve Teknolojik Arascedil;timath;rma Kurumu
dc.description.sponsorshipNo Statement Available
dc.identifier.doi10.1007/s12640-023-00678-9
dc.identifier.issn1029-8428
dc.identifier.issn1476-3524
dc.identifier.issue1
dc.identifier.orcid0000-0002-3470-1783
dc.identifier.orcid0000-0002-5080-5160
dc.identifier.orcid0000-0003-0455-4521
dc.identifier.orcid0000-0003-3755-3015
dc.identifier.pmid38133838
dc.identifier.scopus2-s2.0-85180492828
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s12640-023-00678-9
dc.identifier.urihttps://hdl.handle.net/11508/58505
dc.identifier.volume42
dc.identifier.wosWOS:001127431900002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofNeurotoxicity Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectAsprosin
dc.subjectDiabetes
dc.subjectCell viability
dc.subjectApoptosis
dc.subjectDorsal root ganglion
dc.subjectmiRNA-181a
dc.titleModulation of Neuronal Damage in DRG by Asprosin in a High-Glucose Environment and Its Impact on miRNA181-a Expression in Diabetic DRG
dc.typeArticle

Dosyalar